Related Experiment Videos
Biologic therapies for psoriasis. A systematic review.
Wolf-Henning Boehncke1, Jörg Prinz, Alice B Gottlieb
1Department of Dermatology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany. Boehncke@em.uni-frankfurt.de
The Journal of Rheumatology
|May 26, 2006
Summary
Biologics like alefacept, efalizumab, etanercept, infliximab, and adalimumab offer safe and effective psoriasis treatment options. This review assesses their induction therapy effects and provides preliminary guidelines for personalized patient care.
Area of Science:
- Immunodermatology
- Pharmacology
Background:
- Several biologic agents are approved for moderate to severe plaque psoriasis.
- Ongoing research and clinical trials are expanding treatment options.
- Long-term safety remains an area of uncertainty for some biologics.
Purpose of the Study:
- To review the evidence for five biologic agents used in psoriasis treatment.
- To assess the effects of induction therapy with these biologics.
- To provide preliminary treatment guidelines for matching biologics to patient profiles.
Main Methods:
- Evidence-based literature review.
- Analysis of randomized, double-blind, placebo-controlled clinical studies.
- Assessment of safety profiles, including data from other indications for TNF-a blockers.
Main Results:
- Biologics demonstrate safety and efficacy in treating psoriasis.
- Distinct biologic profiles allow for individualized treatment selection.
- Established evidence supports high-grade recommendations for approved agents.
Conclusions:
- Biologics address unmet medical needs in psoriasis management.
- Matching biologic agents to patient characteristics is crucial for optimal outcomes.
- Preliminary guidelines are proposed to aid in treatment selection.